|
|
Volumn 4, Issue 2, 2005, Pages 99-
|
|
Female sexual dysfunction
a a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AMFEBUTAMONE;
ANDROGEN;
APOMORPHINE;
DOPAMINE RECEPTOR STIMULATING AGENT;
ESTRATEST;
ESTROGEN;
FIBANSERIN;
PHENTOLAMINE MESYLATE;
PHOSPHODIESTERASE V INHIBITOR;
PLACEBO;
PROSTAGLANDIN E1;
SEROTONIN AGONIST;
SILDENAFIL;
TADALAFIL;
TESTOSTERONE;
TESTOSTERONE IVR;
TESTOSTERONE MDTS;
TIBOLONE;
UNCLASSIFIED DRUG;
VASOACTIVE AGENT;
VML 670;
BREAST CANCER;
CARDIOVASCULAR DISEASE;
CLINICAL TRIAL;
DRUG EFFICACY;
DRUG INDUSTRY;
DRUG MARKETING;
DRUG RESEARCH;
DRUG SAFETY;
EPIDEMIOLOGICAL DATA;
FEMALE SEXUAL DYSFUNCTION;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
LIFESTYLE;
MENOPAUSE;
NOTE;
POPULATION RESEARCH;
PRIORITY JOURNAL;
RISK BENEFIT ANALYSIS;
SATISFACTION;
SEXUAL INTERCOURSE;
UNITED STATES;
|
|
EID: 14044266359
PISSN: 14741776
EISSN: None
Source Type: Journal
DOI: 10.1038/nrd1636 Document Type: Note |
|
Times cited : (4)
|
|
References (2)
|
